The Protecting Our Pharmaceutical Supply Chain From China Act of 2020 aims to track?

• A. Track pricing data
• B. Track active pharmaceutical ingredients through an FDA registry
• C. Track finished drug lots
• D. Track medical device components

Answer: (B)

This question tests the idea that the act concentrates on transparency of the pharmaceutical supply chain by tracking active pharmaceutical ingredients through an FDA registry. APIs are the building blocks of medicines, so knowing where they come from, who manufactures them, and how they flow through the system lets regulators identify vulnerabilities, such as overreliance on a single supplier or country, and respond quickly to shortages or quality issues. By centralizing API supplier and manufacturing information in an FDA registry, the goal is to improve safety, reliability, and oversight of drug production.

Tracking pricing data wouldn’t directly address safety or supply chain integrity. Tracking finished drug lots focuses on batches of final products, which is important but downstream and not the API-level visibility this act targets. Tracking medical device components lies outside the pharmaceutical supply chain focus of this legislation.